Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IB/0027/G 
This was an application for a group of variations. 
03/11/2023 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
B.II.e.6.a - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that affects the 
product information 
IA/0026/G 
This was an application for a group of variations. 
01/09/2023 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
II/0025 
B.I.z - Quality change - Active substance - Other 
31/08/2023 
n/a 
variation 
IAIN/0024 
C.I.z - Changes (Safety/Efficacy) of Human and 
30/05/2023 
15/09/2023 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0023/G 
This was an application for a group of variations. 
04/10/2022 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0020 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
22/08/2022 
15/09/2023 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IA/0022/G 
This was an application for a group of variations. 
13/07/2022 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
Page 3/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IA/0021 
A.7 - Administrative change - Deletion of 
27/06/2022 
n/a 
manufacturing sites 
R/0019 
Renewal of the marketing authorisation. 
24/03/2022 
24/05/2022 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
T/0018 
Transfer of Marketing Authorisation 
15/09/2021 
29/09/2021 
SmPC, 
Labelling and 
PL 
IB/0017 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
22/07/2021 
29/09/2021 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
II/0015/G 
This was an application for a group of variations. 
22/07/2021 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.d.1.a.1 - Stability of AS - Change in the re-test 
period/storage period - Reduction 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IB/0016 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
18/04/2021 
29/09/2021 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IA/0014 
A.7 - Administrative change - Deletion of 
23/02/2021 
29/09/2021 
Annex II and 
manufacturing sites 
PL 
IB/0013/G 
This was an application for a group of variations. 
11/02/2021 
29/09/2021 
SmPC, 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Labelling and 
PL 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0012/G 
This was an application for a group of variations. 
19/06/2020 
18/11/2020 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0011/G 
This was an application for a group of variations. 
17/06/2020 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.e - Changes in the manufacturing process of 
Page 8/11 
 
 
 
 
 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
IB/0010 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
14/05/2020 
18/11/2020 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IB/0009 
B.II.e.5.a.2 - Change in pack size of the finished 
27/02/2020 
18/11/2020 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IB/0008 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
05/12/2019 
18/11/2020 
SmPC, 
life of the finished product - After first opening 
(supported by real time data) 
Labelling and 
PL 
IB/0006 
C.I.11.z - Introduction of, or change(s) to, the 
17/06/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0007 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
10/05/2019 
02/08/2019 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
IB/0005/G 
This was an application for a group of variations. 
12/03/2019 
02/08/2019 
SmPC and PL 
Page 9/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0004 
C.I.z - Changes (Safety/Efficacy) of Human and 
27/11/2018 
02/08/2019 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0002 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
15/08/2018 
02/08/2019 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0003/G 
This was an application for a group of variations. 
10/08/2018 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0001/G 
This was an application for a group of variations. 
17/05/2018 
25/06/2018 
SmPC and PL 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 11/11 
 
 
 
 
 
 
 
 
